Share This Author
Emodin Regulates Bone Remodeling by Inhibiting Osteoclastogenesis and Stimulating Osteoblast Formation
- Ju-Young Kim, Yoon‐Hee Cheon, Jaemin Oh
- Biology, MedicineJournal of bone and mineral research : the…
- 1 July 2014
It is shown here that emodin is a potential target for osteoporosis therapeutics, as treatment with this agent enhances osteoblast differentiation and bone growth and suppresses osteoclast differentiate and bone resorption.
Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCγ2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss.
- Ju-Young Kim, Sun-Hyang Park, Myeung-Su Lee
- Biology, MedicineJournal of natural products
- 26 August 2015
Harpagoside inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclastogenesis in vitro and suppresses inflammation-induced bone loss in a mouse model, suggesting that HAR is a valuable agent against inflammation-related bone disorders but not osteoporosis induced by hormonal abnormalities.
Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression.
GM-CSF Regulates Fusion of Mononuclear Osteoclasts into Bone-Resorbing Osteoclasts by Activating the Ras/ERK Pathway1
It is demonstrated that GM-CSF induced fusion of pOCs to form multinucleated osteoclasts, making the osteoclast capable of bone resorption.
Anti-inflammatory activity of fisetin in human mast cells (HMC-1).
Effect of Cornus Officinalis on Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL)-induced Osteoclast Differentiation
- Jung Young Kim, Yun-Kyung Kim, M. Choi, Jaemin Oh, H. Kwak, Jeong-Joong Kim
- Biology, MedicineJournal of bone metabolism
- 1 November 2012
The results suggest that cornus officinalis may be a useful the treatment of osteoporosis.
Downregulation of p38 kinase pathway by cAMP response element-binding protein protects HL-60 cells from iron chelator-induced apoptosis.
Anabolic activity of ursolic acid in bone: Stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo.
Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1…
CGA remarkably attenuated LPS-induced bone loss based on micro-computed tomography and histologic analysis of femurs, suggesting that CGA may be a potential treatment option for osteoclast-related diseases with inflammatory bone destruction.